Review



pdx1 creer  (Jackson Laboratory)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Jackson Laboratory pdx1 creer
    (a) Schematic of alleles and treatments used to inactivate Lsd1 in db/db mice. TM, tamoxifen; wks, weeks. (b) Time course of ad libitum-fed blood glucose levels in TM-treated mice of the indicated genotypes. db/+ Lsd1 fl/+β : n = 7 mice, db/db Lsd1 fl/+β : n = 8 mice, db/db Lsd1 Δβ : n = 11 mice, db/+ Lsd1 Δβ : n = 14 mice. * p <0.05, ** p <0.01, *** p <0.001 between db/db Lsd1 fl/+β and db/db Lsd1 Δβ mice. (c) Glucose tolerance tests in TM-treated mice of the indicated genotypes. db/+ Lsd1 fl/+β : n = 6 mice, db/db Lsd1 Δβ : n = 11 mice, db/db Lsd1 fl/+β : n = 13 mice. * p <0.05, ** p <0.01 between db/db Lsd1 fl/+β and db/db Lsd1 Δβ mice. (d) Serum insulin and blood glucose (glc) levels in mice of the indicated genotypes following a 6-hour fast or 10 min following intraperitoneal injection of glucose. db/+ Lsd1 fl/+β fast and 10’ glucose: n = 4 mice, db/db Lsd1 Δβ 10’ glucose: n = 5 mice, all other groups: n = 6 mice. (e and f) Static insulin secretion assays for islets from the indicated genotypes of mice stimulated with the indicated glucose (glc) concentrations (in mM) with or without 10 nM of exendin-4 (Ex4) or GIP at 7 wks (e) and 9 wks (f) of age. db/+ Lsd1 fl/+β 16.8 mM glc + Ex4 or GIP wk 7: n = 4 pools of 10 islets each, db/+ Lsd1 Δβ 16.8 mM glc + Ex4 or GIP wk 7 and db/db Lsd1 fl/+β 16.8 mM glc + Ex4 wk 7: n = 5 islet pools, db/+ Lsd1 fl/+β 16.8 mM glc wk 7: n = 10 islet pools, db/+ Lsd1 fl/+β 2.8 mM glc wk 9 and db/db Lsd1 fl/+β 16.8 mM glc wk 9: n = 11 islet pools, db/db Lsd1 fl/+β 2.8 mM glc wk 9, db/db Lsd1 Δβ 2.8 mM glc or 16.8 mM glc wk 9, db/+ Lsd1 fl/+β 16.8 mM glc wk 9, and all genotypes 16.8 mM glc + Ex4 wk 9: n = 12 islet pools, all other groups: n = 6 islet pools. (g and h) Islet insulin content for islets from the indicated genotypes of mice. db/+ Lsd1 Δβ wk 7: n = 12 pools of 10 islets each, db/+ Lsd1 fl/+β wk 7: n = 17 islet pools, db/+ Lsd1 Δβ wk 9: n = 23 islet pools, all other groups: n = 24 islet pools. (i) Schematic of S961 administration via transplanted minipumps (20 nmol/week). Veh, vehicle. (j) Time course of ad libitum-fed blood glucose levels in TM-treated Lsd1 fl/+ <t>;</t> <t>Pdx1-CreER</t> mice ( Lsd1 fl/+ β ) and TM-treated Lsd1 fl/fl ; Pdx1-CreER mice ( Lsd1 Δβ ) administered S961 or vehicle. Lsd1 fl/+ β veh: n = 3, Lsd1 Δβ veh: n = 5, Lsd1 fl/+ β S961: n = 7, Lsd1 Δβ S961, n = 9. NS, not significant between S961-treated Lsd1 fl/+ β and Lsd1 Δβ mice. * p <0.05 between Lsd1 fl/+ β and Lsd1 Δβ mice (k and l) Blood glucose levels (k) and serum insulin levels (l) after a 6-hour fast in Lsd1 fl/+ β and Lsd1 Δβ treated with S961 or vehicle for the indicated weeks. Lsd1 fl/+ β veh: n = 3, Lsd1 Δβ veh: n = 5, Lsd1 fl/+ β S961: n = 7, Lsd1 Δβ S961, n = 9. Significance was determined by one-way ANOVA followed by Student’s t-test with Welch’s correction for unequal variance as necessary followed by Dunnett’s multiple comparisons test (g and h) or by two-way ANOVA for treatment or genotype interaction with time or stimulation condition followed by Sidak’s (b, c, j) or Benjamini, Krieger and Yekutieli multiple comparisons test (d - f, k, l). * p <0.05, ** p <0.01, *** p <0.001; NS, not significant.
    Pdx1 Creer, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pdx1+creer/bio_rxiv__64898__2026__05__13__725004-123-11-15?v=Jackson+Laboratory
    Average 86 stars, based on 1 article reviews
    pdx1 creer - by Bioz Stars, 2026-07
    86/100 stars

    Images

    1) Product Images from "Workload-induced changes to cell state contribute to β-cell failure in diabetes"

    Article Title: Workload-induced changes to cell state contribute to β-cell failure in diabetes

    Journal: bioRxiv

    doi: 10.64898/2026.05.13.725004

    (a) Schematic of alleles and treatments used to inactivate Lsd1 in db/db mice. TM, tamoxifen; wks, weeks. (b) Time course of ad libitum-fed blood glucose levels in TM-treated mice of the indicated genotypes. db/+ Lsd1 fl/+β : n = 7 mice, db/db Lsd1 fl/+β : n = 8 mice, db/db Lsd1 Δβ : n = 11 mice, db/+ Lsd1 Δβ : n = 14 mice. * p <0.05, ** p <0.01, *** p <0.001 between db/db Lsd1 fl/+β and db/db Lsd1 Δβ mice. (c) Glucose tolerance tests in TM-treated mice of the indicated genotypes. db/+ Lsd1 fl/+β : n = 6 mice, db/db Lsd1 Δβ : n = 11 mice, db/db Lsd1 fl/+β : n = 13 mice. * p <0.05, ** p <0.01 between db/db Lsd1 fl/+β and db/db Lsd1 Δβ mice. (d) Serum insulin and blood glucose (glc) levels in mice of the indicated genotypes following a 6-hour fast or 10 min following intraperitoneal injection of glucose. db/+ Lsd1 fl/+β fast and 10’ glucose: n = 4 mice, db/db Lsd1 Δβ 10’ glucose: n = 5 mice, all other groups: n = 6 mice. (e and f) Static insulin secretion assays for islets from the indicated genotypes of mice stimulated with the indicated glucose (glc) concentrations (in mM) with or without 10 nM of exendin-4 (Ex4) or GIP at 7 wks (e) and 9 wks (f) of age. db/+ Lsd1 fl/+β 16.8 mM glc + Ex4 or GIP wk 7: n = 4 pools of 10 islets each, db/+ Lsd1 Δβ 16.8 mM glc + Ex4 or GIP wk 7 and db/db Lsd1 fl/+β 16.8 mM glc + Ex4 wk 7: n = 5 islet pools, db/+ Lsd1 fl/+β 16.8 mM glc wk 7: n = 10 islet pools, db/+ Lsd1 fl/+β 2.8 mM glc wk 9 and db/db Lsd1 fl/+β 16.8 mM glc wk 9: n = 11 islet pools, db/db Lsd1 fl/+β 2.8 mM glc wk 9, db/db Lsd1 Δβ 2.8 mM glc or 16.8 mM glc wk 9, db/+ Lsd1 fl/+β 16.8 mM glc wk 9, and all genotypes 16.8 mM glc + Ex4 wk 9: n = 12 islet pools, all other groups: n = 6 islet pools. (g and h) Islet insulin content for islets from the indicated genotypes of mice. db/+ Lsd1 Δβ wk 7: n = 12 pools of 10 islets each, db/+ Lsd1 fl/+β wk 7: n = 17 islet pools, db/+ Lsd1 Δβ wk 9: n = 23 islet pools, all other groups: n = 24 islet pools. (i) Schematic of S961 administration via transplanted minipumps (20 nmol/week). Veh, vehicle. (j) Time course of ad libitum-fed blood glucose levels in TM-treated Lsd1 fl/+ ; Pdx1-CreER mice ( Lsd1 fl/+ β ) and TM-treated Lsd1 fl/fl ; Pdx1-CreER mice ( Lsd1 Δβ ) administered S961 or vehicle. Lsd1 fl/+ β veh: n = 3, Lsd1 Δβ veh: n = 5, Lsd1 fl/+ β S961: n = 7, Lsd1 Δβ S961, n = 9. NS, not significant between S961-treated Lsd1 fl/+ β and Lsd1 Δβ mice. * p <0.05 between Lsd1 fl/+ β and Lsd1 Δβ mice (k and l) Blood glucose levels (k) and serum insulin levels (l) after a 6-hour fast in Lsd1 fl/+ β and Lsd1 Δβ treated with S961 or vehicle for the indicated weeks. Lsd1 fl/+ β veh: n = 3, Lsd1 Δβ veh: n = 5, Lsd1 fl/+ β S961: n = 7, Lsd1 Δβ S961, n = 9. Significance was determined by one-way ANOVA followed by Student’s t-test with Welch’s correction for unequal variance as necessary followed by Dunnett’s multiple comparisons test (g and h) or by two-way ANOVA for treatment or genotype interaction with time or stimulation condition followed by Sidak’s (b, c, j) or Benjamini, Krieger and Yekutieli multiple comparisons test (d - f, k, l). * p <0.05, ** p <0.01, *** p <0.001; NS, not significant.
    Figure Legend Snippet: (a) Schematic of alleles and treatments used to inactivate Lsd1 in db/db mice. TM, tamoxifen; wks, weeks. (b) Time course of ad libitum-fed blood glucose levels in TM-treated mice of the indicated genotypes. db/+ Lsd1 fl/+β : n = 7 mice, db/db Lsd1 fl/+β : n = 8 mice, db/db Lsd1 Δβ : n = 11 mice, db/+ Lsd1 Δβ : n = 14 mice. * p <0.05, ** p <0.01, *** p <0.001 between db/db Lsd1 fl/+β and db/db Lsd1 Δβ mice. (c) Glucose tolerance tests in TM-treated mice of the indicated genotypes. db/+ Lsd1 fl/+β : n = 6 mice, db/db Lsd1 Δβ : n = 11 mice, db/db Lsd1 fl/+β : n = 13 mice. * p <0.05, ** p <0.01 between db/db Lsd1 fl/+β and db/db Lsd1 Δβ mice. (d) Serum insulin and blood glucose (glc) levels in mice of the indicated genotypes following a 6-hour fast or 10 min following intraperitoneal injection of glucose. db/+ Lsd1 fl/+β fast and 10’ glucose: n = 4 mice, db/db Lsd1 Δβ 10’ glucose: n = 5 mice, all other groups: n = 6 mice. (e and f) Static insulin secretion assays for islets from the indicated genotypes of mice stimulated with the indicated glucose (glc) concentrations (in mM) with or without 10 nM of exendin-4 (Ex4) or GIP at 7 wks (e) and 9 wks (f) of age. db/+ Lsd1 fl/+β 16.8 mM glc + Ex4 or GIP wk 7: n = 4 pools of 10 islets each, db/+ Lsd1 Δβ 16.8 mM glc + Ex4 or GIP wk 7 and db/db Lsd1 fl/+β 16.8 mM glc + Ex4 wk 7: n = 5 islet pools, db/+ Lsd1 fl/+β 16.8 mM glc wk 7: n = 10 islet pools, db/+ Lsd1 fl/+β 2.8 mM glc wk 9 and db/db Lsd1 fl/+β 16.8 mM glc wk 9: n = 11 islet pools, db/db Lsd1 fl/+β 2.8 mM glc wk 9, db/db Lsd1 Δβ 2.8 mM glc or 16.8 mM glc wk 9, db/+ Lsd1 fl/+β 16.8 mM glc wk 9, and all genotypes 16.8 mM glc + Ex4 wk 9: n = 12 islet pools, all other groups: n = 6 islet pools. (g and h) Islet insulin content for islets from the indicated genotypes of mice. db/+ Lsd1 Δβ wk 7: n = 12 pools of 10 islets each, db/+ Lsd1 fl/+β wk 7: n = 17 islet pools, db/+ Lsd1 Δβ wk 9: n = 23 islet pools, all other groups: n = 24 islet pools. (i) Schematic of S961 administration via transplanted minipumps (20 nmol/week). Veh, vehicle. (j) Time course of ad libitum-fed blood glucose levels in TM-treated Lsd1 fl/+ ; Pdx1-CreER mice ( Lsd1 fl/+ β ) and TM-treated Lsd1 fl/fl ; Pdx1-CreER mice ( Lsd1 Δβ ) administered S961 or vehicle. Lsd1 fl/+ β veh: n = 3, Lsd1 Δβ veh: n = 5, Lsd1 fl/+ β S961: n = 7, Lsd1 Δβ S961, n = 9. NS, not significant between S961-treated Lsd1 fl/+ β and Lsd1 Δβ mice. * p <0.05 between Lsd1 fl/+ β and Lsd1 Δβ mice (k and l) Blood glucose levels (k) and serum insulin levels (l) after a 6-hour fast in Lsd1 fl/+ β and Lsd1 Δβ treated with S961 or vehicle for the indicated weeks. Lsd1 fl/+ β veh: n = 3, Lsd1 Δβ veh: n = 5, Lsd1 fl/+ β S961: n = 7, Lsd1 Δβ S961, n = 9. Significance was determined by one-way ANOVA followed by Student’s t-test with Welch’s correction for unequal variance as necessary followed by Dunnett’s multiple comparisons test (g and h) or by two-way ANOVA for treatment or genotype interaction with time or stimulation condition followed by Sidak’s (b, c, j) or Benjamini, Krieger and Yekutieli multiple comparisons test (d - f, k, l). * p <0.05, ** p <0.01, *** p <0.001; NS, not significant.

    Techniques Used: Injection



    Similar Products

    pdx1 creer  (Jackson Laboratory)
    86
    Jackson Laboratory pdx1 creer
    (a) Schematic of alleles and treatments used to inactivate Lsd1 in db/db mice. TM, tamoxifen; wks, weeks. (b) Time course of ad libitum-fed blood glucose levels in TM-treated mice of the indicated genotypes. db/+ Lsd1 fl/+β : n = 7 mice, db/db Lsd1 fl/+β : n = 8 mice, db/db Lsd1 Δβ : n = 11 mice, db/+ Lsd1 Δβ : n = 14 mice. * p <0.05, ** p <0.01, *** p <0.001 between db/db Lsd1 fl/+β and db/db Lsd1 Δβ mice. (c) Glucose tolerance tests in TM-treated mice of the indicated genotypes. db/+ Lsd1 fl/+β : n = 6 mice, db/db Lsd1 Δβ : n = 11 mice, db/db Lsd1 fl/+β : n = 13 mice. * p <0.05, ** p <0.01 between db/db Lsd1 fl/+β and db/db Lsd1 Δβ mice. (d) Serum insulin and blood glucose (glc) levels in mice of the indicated genotypes following a 6-hour fast or 10 min following intraperitoneal injection of glucose. db/+ Lsd1 fl/+β fast and 10’ glucose: n = 4 mice, db/db Lsd1 Δβ 10’ glucose: n = 5 mice, all other groups: n = 6 mice. (e and f) Static insulin secretion assays for islets from the indicated genotypes of mice stimulated with the indicated glucose (glc) concentrations (in mM) with or without 10 nM of exendin-4 (Ex4) or GIP at 7 wks (e) and 9 wks (f) of age. db/+ Lsd1 fl/+β 16.8 mM glc + Ex4 or GIP wk 7: n = 4 pools of 10 islets each, db/+ Lsd1 Δβ 16.8 mM glc + Ex4 or GIP wk 7 and db/db Lsd1 fl/+β 16.8 mM glc + Ex4 wk 7: n = 5 islet pools, db/+ Lsd1 fl/+β 16.8 mM glc wk 7: n = 10 islet pools, db/+ Lsd1 fl/+β 2.8 mM glc wk 9 and db/db Lsd1 fl/+β 16.8 mM glc wk 9: n = 11 islet pools, db/db Lsd1 fl/+β 2.8 mM glc wk 9, db/db Lsd1 Δβ 2.8 mM glc or 16.8 mM glc wk 9, db/+ Lsd1 fl/+β 16.8 mM glc wk 9, and all genotypes 16.8 mM glc + Ex4 wk 9: n = 12 islet pools, all other groups: n = 6 islet pools. (g and h) Islet insulin content for islets from the indicated genotypes of mice. db/+ Lsd1 Δβ wk 7: n = 12 pools of 10 islets each, db/+ Lsd1 fl/+β wk 7: n = 17 islet pools, db/+ Lsd1 Δβ wk 9: n = 23 islet pools, all other groups: n = 24 islet pools. (i) Schematic of S961 administration via transplanted minipumps (20 nmol/week). Veh, vehicle. (j) Time course of ad libitum-fed blood glucose levels in TM-treated Lsd1 fl/+ <t>;</t> <t>Pdx1-CreER</t> mice ( Lsd1 fl/+ β ) and TM-treated Lsd1 fl/fl ; Pdx1-CreER mice ( Lsd1 Δβ ) administered S961 or vehicle. Lsd1 fl/+ β veh: n = 3, Lsd1 Δβ veh: n = 5, Lsd1 fl/+ β S961: n = 7, Lsd1 Δβ S961, n = 9. NS, not significant between S961-treated Lsd1 fl/+ β and Lsd1 Δβ mice. * p <0.05 between Lsd1 fl/+ β and Lsd1 Δβ mice (k and l) Blood glucose levels (k) and serum insulin levels (l) after a 6-hour fast in Lsd1 fl/+ β and Lsd1 Δβ treated with S961 or vehicle for the indicated weeks. Lsd1 fl/+ β veh: n = 3, Lsd1 Δβ veh: n = 5, Lsd1 fl/+ β S961: n = 7, Lsd1 Δβ S961, n = 9. Significance was determined by one-way ANOVA followed by Student’s t-test with Welch’s correction for unequal variance as necessary followed by Dunnett’s multiple comparisons test (g and h) or by two-way ANOVA for treatment or genotype interaction with time or stimulation condition followed by Sidak’s (b, c, j) or Benjamini, Krieger and Yekutieli multiple comparisons test (d - f, k, l). * p <0.05, ** p <0.01, *** p <0.001; NS, not significant.
    Pdx1 Creer, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pdx1+creer/bio_rxiv__64898__2026__05__13__725004-123-11-15?v=Jackson+Laboratory
    Average 86 stars, based on 1 article reviews
    pdx1 creer - by Bioz Stars, 2026-07
    86/100 stars
    		  Buy from Supplier
    mouse pdx1 creer  (Jackson Laboratory)
    86
    Jackson Laboratory mouse pdx1 creer
    (a) Schematic of alleles and treatments used to inactivate Lsd1 in db/db mice. TM, tamoxifen; wks, weeks. (b) Time course of ad libitum-fed blood glucose levels in TM-treated mice of the indicated genotypes. db/+ Lsd1 fl/+β : n = 7 mice, db/db Lsd1 fl/+β : n = 8 mice, db/db Lsd1 Δβ : n = 11 mice, db/+ Lsd1 Δβ : n = 14 mice. * p <0.05, ** p <0.01, *** p <0.001 between db/db Lsd1 fl/+β and db/db Lsd1 Δβ mice. (c) Glucose tolerance tests in TM-treated mice of the indicated genotypes. db/+ Lsd1 fl/+β : n = 6 mice, db/db Lsd1 Δβ : n = 11 mice, db/db Lsd1 fl/+β : n = 13 mice. * p <0.05, ** p <0.01 between db/db Lsd1 fl/+β and db/db Lsd1 Δβ mice. (d) Serum insulin and blood glucose (glc) levels in mice of the indicated genotypes following a 6-hour fast or 10 min following intraperitoneal injection of glucose. db/+ Lsd1 fl/+β fast and 10’ glucose: n = 4 mice, db/db Lsd1 Δβ 10’ glucose: n = 5 mice, all other groups: n = 6 mice. (e and f) Static insulin secretion assays for islets from the indicated genotypes of mice stimulated with the indicated glucose (glc) concentrations (in mM) with or without 10 nM of exendin-4 (Ex4) or GIP at 7 wks (e) and 9 wks (f) of age. db/+ Lsd1 fl/+β 16.8 mM glc + Ex4 or GIP wk 7: n = 4 pools of 10 islets each, db/+ Lsd1 Δβ 16.8 mM glc + Ex4 or GIP wk 7 and db/db Lsd1 fl/+β 16.8 mM glc + Ex4 wk 7: n = 5 islet pools, db/+ Lsd1 fl/+β 16.8 mM glc wk 7: n = 10 islet pools, db/+ Lsd1 fl/+β 2.8 mM glc wk 9 and db/db Lsd1 fl/+β 16.8 mM glc wk 9: n = 11 islet pools, db/db Lsd1 fl/+β 2.8 mM glc wk 9, db/db Lsd1 Δβ 2.8 mM glc or 16.8 mM glc wk 9, db/+ Lsd1 fl/+β 16.8 mM glc wk 9, and all genotypes 16.8 mM glc + Ex4 wk 9: n = 12 islet pools, all other groups: n = 6 islet pools. (g and h) Islet insulin content for islets from the indicated genotypes of mice. db/+ Lsd1 Δβ wk 7: n = 12 pools of 10 islets each, db/+ Lsd1 fl/+β wk 7: n = 17 islet pools, db/+ Lsd1 Δβ wk 9: n = 23 islet pools, all other groups: n = 24 islet pools. (i) Schematic of S961 administration via transplanted minipumps (20 nmol/week). Veh, vehicle. (j) Time course of ad libitum-fed blood glucose levels in TM-treated Lsd1 fl/+ <t>;</t> <t>Pdx1-CreER</t> mice ( Lsd1 fl/+ β ) and TM-treated Lsd1 fl/fl ; Pdx1-CreER mice ( Lsd1 Δβ ) administered S961 or vehicle. Lsd1 fl/+ β veh: n = 3, Lsd1 Δβ veh: n = 5, Lsd1 fl/+ β S961: n = 7, Lsd1 Δβ S961, n = 9. NS, not significant between S961-treated Lsd1 fl/+ β and Lsd1 Δβ mice. * p <0.05 between Lsd1 fl/+ β and Lsd1 Δβ mice (k and l) Blood glucose levels (k) and serum insulin levels (l) after a 6-hour fast in Lsd1 fl/+ β and Lsd1 Δβ treated with S961 or vehicle for the indicated weeks. Lsd1 fl/+ β veh: n = 3, Lsd1 Δβ veh: n = 5, Lsd1 fl/+ β S961: n = 7, Lsd1 Δβ S961, n = 9. Significance was determined by one-way ANOVA followed by Student’s t-test with Welch’s correction for unequal variance as necessary followed by Dunnett’s multiple comparisons test (g and h) or by two-way ANOVA for treatment or genotype interaction with time or stimulation condition followed by Sidak’s (b, c, j) or Benjamini, Krieger and Yekutieli multiple comparisons test (d - f, k, l). * p <0.05, ** p <0.01, *** p <0.001; NS, not significant.
    Mouse Pdx1 Creer, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pdx1+creer/pmc12693725-733-0-4?v=Jackson+Laboratory
    Average 86 stars, based on 1 article reviews
    mouse pdx1 creer - by Bioz Stars, 2026-07
    86/100 stars
    		  Buy from Supplier
    kraslsl g12d tp53flox flox pdx1 creer  (Jackson Laboratory)
    86
    Jackson Laboratory kraslsl g12d tp53flox flox pdx1 creer
    (a) Schematic of alleles and treatments used to inactivate Lsd1 in db/db mice. TM, tamoxifen; wks, weeks. (b) Time course of ad libitum-fed blood glucose levels in TM-treated mice of the indicated genotypes. db/+ Lsd1 fl/+β : n = 7 mice, db/db Lsd1 fl/+β : n = 8 mice, db/db Lsd1 Δβ : n = 11 mice, db/+ Lsd1 Δβ : n = 14 mice. * p <0.05, ** p <0.01, *** p <0.001 between db/db Lsd1 fl/+β and db/db Lsd1 Δβ mice. (c) Glucose tolerance tests in TM-treated mice of the indicated genotypes. db/+ Lsd1 fl/+β : n = 6 mice, db/db Lsd1 Δβ : n = 11 mice, db/db Lsd1 fl/+β : n = 13 mice. * p <0.05, ** p <0.01 between db/db Lsd1 fl/+β and db/db Lsd1 Δβ mice. (d) Serum insulin and blood glucose (glc) levels in mice of the indicated genotypes following a 6-hour fast or 10 min following intraperitoneal injection of glucose. db/+ Lsd1 fl/+β fast and 10’ glucose: n = 4 mice, db/db Lsd1 Δβ 10’ glucose: n = 5 mice, all other groups: n = 6 mice. (e and f) Static insulin secretion assays for islets from the indicated genotypes of mice stimulated with the indicated glucose (glc) concentrations (in mM) with or without 10 nM of exendin-4 (Ex4) or GIP at 7 wks (e) and 9 wks (f) of age. db/+ Lsd1 fl/+β 16.8 mM glc + Ex4 or GIP wk 7: n = 4 pools of 10 islets each, db/+ Lsd1 Δβ 16.8 mM glc + Ex4 or GIP wk 7 and db/db Lsd1 fl/+β 16.8 mM glc + Ex4 wk 7: n = 5 islet pools, db/+ Lsd1 fl/+β 16.8 mM glc wk 7: n = 10 islet pools, db/+ Lsd1 fl/+β 2.8 mM glc wk 9 and db/db Lsd1 fl/+β 16.8 mM glc wk 9: n = 11 islet pools, db/db Lsd1 fl/+β 2.8 mM glc wk 9, db/db Lsd1 Δβ 2.8 mM glc or 16.8 mM glc wk 9, db/+ Lsd1 fl/+β 16.8 mM glc wk 9, and all genotypes 16.8 mM glc + Ex4 wk 9: n = 12 islet pools, all other groups: n = 6 islet pools. (g and h) Islet insulin content for islets from the indicated genotypes of mice. db/+ Lsd1 Δβ wk 7: n = 12 pools of 10 islets each, db/+ Lsd1 fl/+β wk 7: n = 17 islet pools, db/+ Lsd1 Δβ wk 9: n = 23 islet pools, all other groups: n = 24 islet pools. (i) Schematic of S961 administration via transplanted minipumps (20 nmol/week). Veh, vehicle. (j) Time course of ad libitum-fed blood glucose levels in TM-treated Lsd1 fl/+ <t>;</t> <t>Pdx1-CreER</t> mice ( Lsd1 fl/+ β ) and TM-treated Lsd1 fl/fl ; Pdx1-CreER mice ( Lsd1 Δβ ) administered S961 or vehicle. Lsd1 fl/+ β veh: n = 3, Lsd1 Δβ veh: n = 5, Lsd1 fl/+ β S961: n = 7, Lsd1 Δβ S961, n = 9. NS, not significant between S961-treated Lsd1 fl/+ β and Lsd1 Δβ mice. * p <0.05 between Lsd1 fl/+ β and Lsd1 Δβ mice (k and l) Blood glucose levels (k) and serum insulin levels (l) after a 6-hour fast in Lsd1 fl/+ β and Lsd1 Δβ treated with S961 or vehicle for the indicated weeks. Lsd1 fl/+ β veh: n = 3, Lsd1 Δβ veh: n = 5, Lsd1 fl/+ β S961: n = 7, Lsd1 Δβ S961, n = 9. Significance was determined by one-way ANOVA followed by Student’s t-test with Welch’s correction for unequal variance as necessary followed by Dunnett’s multiple comparisons test (g and h) or by two-way ANOVA for treatment or genotype interaction with time or stimulation condition followed by Sidak’s (b, c, j) or Benjamini, Krieger and Yekutieli multiple comparisons test (d - f, k, l). * p <0.05, ** p <0.01, *** p <0.001; NS, not significant.
    Kraslsl G12d Tp53flox Flox Pdx1 Creer, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pdx1+creer/pmc12445075-69-1-3?v=Jackson+Laboratory
    Average 86 stars, based on 1 article reviews
    kraslsl g12d tp53flox flox pdx1 creer - by Bioz Stars, 2026-07
    86/100 stars
    		  Buy from Supplier
    kraslsl-g12d; p53loxp; pdx1-creer (kpc#03 2429) tam-induced pdac model mice  (Jackson Laboratory)
    90
    Jackson Laboratory kraslsl-g12d; p53loxp; pdx1-creer (kpc#03 2429) tam-induced pdac model mice
    (a) Schematic of alleles and treatments used to inactivate Lsd1 in db/db mice. TM, tamoxifen; wks, weeks. (b) Time course of ad libitum-fed blood glucose levels in TM-treated mice of the indicated genotypes. db/+ Lsd1 fl/+β : n = 7 mice, db/db Lsd1 fl/+β : n = 8 mice, db/db Lsd1 Δβ : n = 11 mice, db/+ Lsd1 Δβ : n = 14 mice. * p <0.05, ** p <0.01, *** p <0.001 between db/db Lsd1 fl/+β and db/db Lsd1 Δβ mice. (c) Glucose tolerance tests in TM-treated mice of the indicated genotypes. db/+ Lsd1 fl/+β : n = 6 mice, db/db Lsd1 Δβ : n = 11 mice, db/db Lsd1 fl/+β : n = 13 mice. * p <0.05, ** p <0.01 between db/db Lsd1 fl/+β and db/db Lsd1 Δβ mice. (d) Serum insulin and blood glucose (glc) levels in mice of the indicated genotypes following a 6-hour fast or 10 min following intraperitoneal injection of glucose. db/+ Lsd1 fl/+β fast and 10’ glucose: n = 4 mice, db/db Lsd1 Δβ 10’ glucose: n = 5 mice, all other groups: n = 6 mice. (e and f) Static insulin secretion assays for islets from the indicated genotypes of mice stimulated with the indicated glucose (glc) concentrations (in mM) with or without 10 nM of exendin-4 (Ex4) or GIP at 7 wks (e) and 9 wks (f) of age. db/+ Lsd1 fl/+β 16.8 mM glc + Ex4 or GIP wk 7: n = 4 pools of 10 islets each, db/+ Lsd1 Δβ 16.8 mM glc + Ex4 or GIP wk 7 and db/db Lsd1 fl/+β 16.8 mM glc + Ex4 wk 7: n = 5 islet pools, db/+ Lsd1 fl/+β 16.8 mM glc wk 7: n = 10 islet pools, db/+ Lsd1 fl/+β 2.8 mM glc wk 9 and db/db Lsd1 fl/+β 16.8 mM glc wk 9: n = 11 islet pools, db/db Lsd1 fl/+β 2.8 mM glc wk 9, db/db Lsd1 Δβ 2.8 mM glc or 16.8 mM glc wk 9, db/+ Lsd1 fl/+β 16.8 mM glc wk 9, and all genotypes 16.8 mM glc + Ex4 wk 9: n = 12 islet pools, all other groups: n = 6 islet pools. (g and h) Islet insulin content for islets from the indicated genotypes of mice. db/+ Lsd1 Δβ wk 7: n = 12 pools of 10 islets each, db/+ Lsd1 fl/+β wk 7: n = 17 islet pools, db/+ Lsd1 Δβ wk 9: n = 23 islet pools, all other groups: n = 24 islet pools. (i) Schematic of S961 administration via transplanted minipumps (20 nmol/week). Veh, vehicle. (j) Time course of ad libitum-fed blood glucose levels in TM-treated Lsd1 fl/+ <t>;</t> <t>Pdx1-CreER</t> mice ( Lsd1 fl/+ β ) and TM-treated Lsd1 fl/fl ; Pdx1-CreER mice ( Lsd1 Δβ ) administered S961 or vehicle. Lsd1 fl/+ β veh: n = 3, Lsd1 Δβ veh: n = 5, Lsd1 fl/+ β S961: n = 7, Lsd1 Δβ S961, n = 9. NS, not significant between S961-treated Lsd1 fl/+ β and Lsd1 Δβ mice. * p <0.05 between Lsd1 fl/+ β and Lsd1 Δβ mice (k and l) Blood glucose levels (k) and serum insulin levels (l) after a 6-hour fast in Lsd1 fl/+ β and Lsd1 Δβ treated with S961 or vehicle for the indicated weeks. Lsd1 fl/+ β veh: n = 3, Lsd1 Δβ veh: n = 5, Lsd1 fl/+ β S961: n = 7, Lsd1 Δβ S961, n = 9. Significance was determined by one-way ANOVA followed by Student’s t-test with Welch’s correction for unequal variance as necessary followed by Dunnett’s multiple comparisons test (g and h) or by two-way ANOVA for treatment or genotype interaction with time or stimulation condition followed by Sidak’s (b, c, j) or Benjamini, Krieger and Yekutieli multiple comparisons test (d - f, k, l). * p <0.05, ** p <0.01, *** p <0.001; NS, not significant.
    Kraslsl G12d; P53loxp; Pdx1 Creer (Kpc#03 2429) Tam Induced Pdac Model Mice, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pdx1+creer/pm39329457-249-7-25?v=Jackson+Laboratory
    Average 90 stars, based on 1 article reviews
    kraslsl-g12d; p53loxp; pdx1-creer (kpc#03 2429) tam-induced pdac model mice - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier
    kp −/− c tamoxifen-inducible mice (kras lsl-g12d ;p53 loxp ;pdx1-creer)  (Jackson Laboratory)
    90
    Jackson Laboratory kp −/− c tamoxifen-inducible mice (kras lsl-g12d ;p53 loxp ;pdx1-creer)
    (a) Schematic of alleles and treatments used to inactivate Lsd1 in db/db mice. TM, tamoxifen; wks, weeks. (b) Time course of ad libitum-fed blood glucose levels in TM-treated mice of the indicated genotypes. db/+ Lsd1 fl/+β : n = 7 mice, db/db Lsd1 fl/+β : n = 8 mice, db/db Lsd1 Δβ : n = 11 mice, db/+ Lsd1 Δβ : n = 14 mice. * p <0.05, ** p <0.01, *** p <0.001 between db/db Lsd1 fl/+β and db/db Lsd1 Δβ mice. (c) Glucose tolerance tests in TM-treated mice of the indicated genotypes. db/+ Lsd1 fl/+β : n = 6 mice, db/db Lsd1 Δβ : n = 11 mice, db/db Lsd1 fl/+β : n = 13 mice. * p <0.05, ** p <0.01 between db/db Lsd1 fl/+β and db/db Lsd1 Δβ mice. (d) Serum insulin and blood glucose (glc) levels in mice of the indicated genotypes following a 6-hour fast or 10 min following intraperitoneal injection of glucose. db/+ Lsd1 fl/+β fast and 10’ glucose: n = 4 mice, db/db Lsd1 Δβ 10’ glucose: n = 5 mice, all other groups: n = 6 mice. (e and f) Static insulin secretion assays for islets from the indicated genotypes of mice stimulated with the indicated glucose (glc) concentrations (in mM) with or without 10 nM of exendin-4 (Ex4) or GIP at 7 wks (e) and 9 wks (f) of age. db/+ Lsd1 fl/+β 16.8 mM glc + Ex4 or GIP wk 7: n = 4 pools of 10 islets each, db/+ Lsd1 Δβ 16.8 mM glc + Ex4 or GIP wk 7 and db/db Lsd1 fl/+β 16.8 mM glc + Ex4 wk 7: n = 5 islet pools, db/+ Lsd1 fl/+β 16.8 mM glc wk 7: n = 10 islet pools, db/+ Lsd1 fl/+β 2.8 mM glc wk 9 and db/db Lsd1 fl/+β 16.8 mM glc wk 9: n = 11 islet pools, db/db Lsd1 fl/+β 2.8 mM glc wk 9, db/db Lsd1 Δβ 2.8 mM glc or 16.8 mM glc wk 9, db/+ Lsd1 fl/+β 16.8 mM glc wk 9, and all genotypes 16.8 mM glc + Ex4 wk 9: n = 12 islet pools, all other groups: n = 6 islet pools. (g and h) Islet insulin content for islets from the indicated genotypes of mice. db/+ Lsd1 Δβ wk 7: n = 12 pools of 10 islets each, db/+ Lsd1 fl/+β wk 7: n = 17 islet pools, db/+ Lsd1 Δβ wk 9: n = 23 islet pools, all other groups: n = 24 islet pools. (i) Schematic of S961 administration via transplanted minipumps (20 nmol/week). Veh, vehicle. (j) Time course of ad libitum-fed blood glucose levels in TM-treated Lsd1 fl/+ <t>;</t> <t>Pdx1-CreER</t> mice ( Lsd1 fl/+ β ) and TM-treated Lsd1 fl/fl ; Pdx1-CreER mice ( Lsd1 Δβ ) administered S961 or vehicle. Lsd1 fl/+ β veh: n = 3, Lsd1 Δβ veh: n = 5, Lsd1 fl/+ β S961: n = 7, Lsd1 Δβ S961, n = 9. NS, not significant between S961-treated Lsd1 fl/+ β and Lsd1 Δβ mice. * p <0.05 between Lsd1 fl/+ β and Lsd1 Δβ mice (k and l) Blood glucose levels (k) and serum insulin levels (l) after a 6-hour fast in Lsd1 fl/+ β and Lsd1 Δβ treated with S961 or vehicle for the indicated weeks. Lsd1 fl/+ β veh: n = 3, Lsd1 Δβ veh: n = 5, Lsd1 fl/+ β S961: n = 7, Lsd1 Δβ S961, n = 9. Significance was determined by one-way ANOVA followed by Student’s t-test with Welch’s correction for unequal variance as necessary followed by Dunnett’s multiple comparisons test (g and h) or by two-way ANOVA for treatment or genotype interaction with time or stimulation condition followed by Sidak’s (b, c, j) or Benjamini, Krieger and Yekutieli multiple comparisons test (d - f, k, l). * p <0.05, ** p <0.01, *** p <0.001; NS, not significant.
    Kp −/− C Tamoxifen Inducible Mice (Kras Lsl G12d ;P53 Loxp ;Pdx1 Creer), supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pdx1+creer/pmc11403292-121-6-17?v=Jackson+Laboratory
    Average 90 stars, based on 1 article reviews
    kp −/− c tamoxifen-inducible mice (kras lsl-g12d ;p53 loxp ;pdx1-creer) - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier
    pdx1-creer mouse  (Jackson Laboratory)
    90
    Jackson Laboratory pdx1-creer mouse
    Reagents and resources.
    Pdx1 Creer Mouse, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pdx1+creer/pmc10200888-1-3-8?v=Jackson+Laboratory
    Average 90 stars, based on 1 article reviews
    pdx1-creer mouse - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier
    pdx1-creer mouse line  (Jackson Laboratory)
    90
    Jackson Laboratory pdx1-creer mouse line
    Reagents and resources.
    Pdx1 Creer Mouse Line, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pdx1+creer/pmc10068556-460-8-11?v=Jackson+Laboratory
    Average 90 stars, based on 1 article reviews
    pdx1-creer mouse line - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier
    pdx1-creer: tg (pdx1-cre/esr1∗)#dam  (Jackson Laboratory)
    90
    Jackson Laboratory pdx1-creer: tg (pdx1-cre/esr1∗)#dam
    Reagents and resources.
    Pdx1 Creer: Tg (Pdx1 Cre/Esr1∗)#Dam, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pdx1+creer/pmc10068556-77-0-5?v=Jackson+Laboratory
    Average 90 stars, based on 1 article reviews
    pdx1-creer: tg (pdx1-cre/esr1∗)#dam - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier
    pdx1-creer mice  (Jackson Laboratory)
    90
    Jackson Laboratory pdx1-creer mice
    Reagents and resources.
    Pdx1 Creer Mice, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pdx1+creer/pmc09076738__125_2022_5669_MOESM1_ESM-6-11-14?v=Jackson+Laboratory
    Average 90 stars, based on 1 article reviews
    pdx1-creer mice - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    (a) Schematic of alleles and treatments used to inactivate Lsd1 in db/db mice. TM, tamoxifen; wks, weeks. (b) Time course of ad libitum-fed blood glucose levels in TM-treated mice of the indicated genotypes. db/+ Lsd1 fl/+β : n = 7 mice, db/db Lsd1 fl/+β : n = 8 mice, db/db Lsd1 Δβ : n = 11 mice, db/+ Lsd1 Δβ : n = 14 mice. * p <0.05, ** p <0.01, *** p <0.001 between db/db Lsd1 fl/+β and db/db Lsd1 Δβ mice. (c) Glucose tolerance tests in TM-treated mice of the indicated genotypes. db/+ Lsd1 fl/+β : n = 6 mice, db/db Lsd1 Δβ : n = 11 mice, db/db Lsd1 fl/+β : n = 13 mice. * p <0.05, ** p <0.01 between db/db Lsd1 fl/+β and db/db Lsd1 Δβ mice. (d) Serum insulin and blood glucose (glc) levels in mice of the indicated genotypes following a 6-hour fast or 10 min following intraperitoneal injection of glucose. db/+ Lsd1 fl/+β fast and 10’ glucose: n = 4 mice, db/db Lsd1 Δβ 10’ glucose: n = 5 mice, all other groups: n = 6 mice. (e and f) Static insulin secretion assays for islets from the indicated genotypes of mice stimulated with the indicated glucose (glc) concentrations (in mM) with or without 10 nM of exendin-4 (Ex4) or GIP at 7 wks (e) and 9 wks (f) of age. db/+ Lsd1 fl/+β 16.8 mM glc + Ex4 or GIP wk 7: n = 4 pools of 10 islets each, db/+ Lsd1 Δβ 16.8 mM glc + Ex4 or GIP wk 7 and db/db Lsd1 fl/+β 16.8 mM glc + Ex4 wk 7: n = 5 islet pools, db/+ Lsd1 fl/+β 16.8 mM glc wk 7: n = 10 islet pools, db/+ Lsd1 fl/+β 2.8 mM glc wk 9 and db/db Lsd1 fl/+β 16.8 mM glc wk 9: n = 11 islet pools, db/db Lsd1 fl/+β 2.8 mM glc wk 9, db/db Lsd1 Δβ 2.8 mM glc or 16.8 mM glc wk 9, db/+ Lsd1 fl/+β 16.8 mM glc wk 9, and all genotypes 16.8 mM glc + Ex4 wk 9: n = 12 islet pools, all other groups: n = 6 islet pools. (g and h) Islet insulin content for islets from the indicated genotypes of mice. db/+ Lsd1 Δβ wk 7: n = 12 pools of 10 islets each, db/+ Lsd1 fl/+β wk 7: n = 17 islet pools, db/+ Lsd1 Δβ wk 9: n = 23 islet pools, all other groups: n = 24 islet pools. (i) Schematic of S961 administration via transplanted minipumps (20 nmol/week). Veh, vehicle. (j) Time course of ad libitum-fed blood glucose levels in TM-treated Lsd1 fl/+ ; Pdx1-CreER mice ( Lsd1 fl/+ β ) and TM-treated Lsd1 fl/fl ; Pdx1-CreER mice ( Lsd1 Δβ ) administered S961 or vehicle. Lsd1 fl/+ β veh: n = 3, Lsd1 Δβ veh: n = 5, Lsd1 fl/+ β S961: n = 7, Lsd1 Δβ S961, n = 9. NS, not significant between S961-treated Lsd1 fl/+ β and Lsd1 Δβ mice. * p <0.05 between Lsd1 fl/+ β and Lsd1 Δβ mice (k and l) Blood glucose levels (k) and serum insulin levels (l) after a 6-hour fast in Lsd1 fl/+ β and Lsd1 Δβ treated with S961 or vehicle for the indicated weeks. Lsd1 fl/+ β veh: n = 3, Lsd1 Δβ veh: n = 5, Lsd1 fl/+ β S961: n = 7, Lsd1 Δβ S961, n = 9. Significance was determined by one-way ANOVA followed by Student’s t-test with Welch’s correction for unequal variance as necessary followed by Dunnett’s multiple comparisons test (g and h) or by two-way ANOVA for treatment or genotype interaction with time or stimulation condition followed by Sidak’s (b, c, j) or Benjamini, Krieger and Yekutieli multiple comparisons test (d - f, k, l). * p <0.05, ** p <0.01, *** p <0.001; NS, not significant.

    Journal: bioRxiv

    Article Title: Workload-induced changes to cell state contribute to β-cell failure in diabetes

    doi: 10.64898/2026.05.13.725004

    Figure Lengend Snippet: (a) Schematic of alleles and treatments used to inactivate Lsd1 in db/db mice. TM, tamoxifen; wks, weeks. (b) Time course of ad libitum-fed blood glucose levels in TM-treated mice of the indicated genotypes. db/+ Lsd1 fl/+β : n = 7 mice, db/db Lsd1 fl/+β : n = 8 mice, db/db Lsd1 Δβ : n = 11 mice, db/+ Lsd1 Δβ : n = 14 mice. * p <0.05, ** p <0.01, *** p <0.001 between db/db Lsd1 fl/+β and db/db Lsd1 Δβ mice. (c) Glucose tolerance tests in TM-treated mice of the indicated genotypes. db/+ Lsd1 fl/+β : n = 6 mice, db/db Lsd1 Δβ : n = 11 mice, db/db Lsd1 fl/+β : n = 13 mice. * p <0.05, ** p <0.01 between db/db Lsd1 fl/+β and db/db Lsd1 Δβ mice. (d) Serum insulin and blood glucose (glc) levels in mice of the indicated genotypes following a 6-hour fast or 10 min following intraperitoneal injection of glucose. db/+ Lsd1 fl/+β fast and 10’ glucose: n = 4 mice, db/db Lsd1 Δβ 10’ glucose: n = 5 mice, all other groups: n = 6 mice. (e and f) Static insulin secretion assays for islets from the indicated genotypes of mice stimulated with the indicated glucose (glc) concentrations (in mM) with or without 10 nM of exendin-4 (Ex4) or GIP at 7 wks (e) and 9 wks (f) of age. db/+ Lsd1 fl/+β 16.8 mM glc + Ex4 or GIP wk 7: n = 4 pools of 10 islets each, db/+ Lsd1 Δβ 16.8 mM glc + Ex4 or GIP wk 7 and db/db Lsd1 fl/+β 16.8 mM glc + Ex4 wk 7: n = 5 islet pools, db/+ Lsd1 fl/+β 16.8 mM glc wk 7: n = 10 islet pools, db/+ Lsd1 fl/+β 2.8 mM glc wk 9 and db/db Lsd1 fl/+β 16.8 mM glc wk 9: n = 11 islet pools, db/db Lsd1 fl/+β 2.8 mM glc wk 9, db/db Lsd1 Δβ 2.8 mM glc or 16.8 mM glc wk 9, db/+ Lsd1 fl/+β 16.8 mM glc wk 9, and all genotypes 16.8 mM glc + Ex4 wk 9: n = 12 islet pools, all other groups: n = 6 islet pools. (g and h) Islet insulin content for islets from the indicated genotypes of mice. db/+ Lsd1 Δβ wk 7: n = 12 pools of 10 islets each, db/+ Lsd1 fl/+β wk 7: n = 17 islet pools, db/+ Lsd1 Δβ wk 9: n = 23 islet pools, all other groups: n = 24 islet pools. (i) Schematic of S961 administration via transplanted minipumps (20 nmol/week). Veh, vehicle. (j) Time course of ad libitum-fed blood glucose levels in TM-treated Lsd1 fl/+ ; Pdx1-CreER mice ( Lsd1 fl/+ β ) and TM-treated Lsd1 fl/fl ; Pdx1-CreER mice ( Lsd1 Δβ ) administered S961 or vehicle. Lsd1 fl/+ β veh: n = 3, Lsd1 Δβ veh: n = 5, Lsd1 fl/+ β S961: n = 7, Lsd1 Δβ S961, n = 9. NS, not significant between S961-treated Lsd1 fl/+ β and Lsd1 Δβ mice. * p <0.05 between Lsd1 fl/+ β and Lsd1 Δβ mice (k and l) Blood glucose levels (k) and serum insulin levels (l) after a 6-hour fast in Lsd1 fl/+ β and Lsd1 Δβ treated with S961 or vehicle for the indicated weeks. Lsd1 fl/+ β veh: n = 3, Lsd1 Δβ veh: n = 5, Lsd1 fl/+ β S961: n = 7, Lsd1 Δβ S961, n = 9. Significance was determined by one-way ANOVA followed by Student’s t-test with Welch’s correction for unequal variance as necessary followed by Dunnett’s multiple comparisons test (g and h) or by two-way ANOVA for treatment or genotype interaction with time or stimulation condition followed by Sidak’s (b, c, j) or Benjamini, Krieger and Yekutieli multiple comparisons test (d - f, k, l). * p <0.05, ** p <0.01, *** p <0.001; NS, not significant.

    Article Snippet: The following strains were used in this study: Lsd1 flox , Pdx1-creER , and db/db (Jackson labs strain 000642).

    Techniques: Injection

    Reagents and resources.

    Journal: Frontiers in Endocrinology

    Article Title: Role of Delta/Notch-like EGF-related receptor in blood glucose homeostasis

    doi: 10.3389/fendo.2023.1161085

    Figure Lengend Snippet: Reagents and resources.

    Article Snippet: Pdx1-CreER mouse , Tg(Pdx1-cre/Esr1*) #Dam/J; Pdx1- cre/Esr1*Dam , The Jackson Laboratory , MGI: 5008261.

    Techniques:

    Primers used for qRT-PCR.

    Journal: Frontiers in Endocrinology

    Article Title: Role of Delta/Notch-like EGF-related receptor in blood glucose homeostasis

    doi: 10.3389/fendo.2023.1161085

    Figure Lengend Snippet: Primers used for qRT-PCR.

    Article Snippet: Pdx1-CreER mouse , Tg(Pdx1-cre/Esr1*) #Dam/J; Pdx1- cre/Esr1*Dam , The Jackson Laboratory , MGI: 5008261.

    Techniques:

    β-cell-cell contacts are disturbed in β-Dner cKO islets due to decreased expression of cell adhesion markers. (A) Immunohistochemistry for E-cadherin (green) and Pdx1 (magenta). Scale bars: 25μm. Representative images from 3 independent experiments. (B) Fluorescence intensity quantifications (arbitrary units) of E-cadherin immunohistochemistry in islets identified by Pdx1-positive immunohistochemistry and exocrine cells identified by DAPI-based nuclear morphology. (N= 3-4 animals per group, 2≥ islets per animal: t-test *p<0.05, ns p>0.05). (C) Immunohistochemistry for NCAM (green) shown in islets and innervating axons on the pancreas. Scale bars: 25μm. Representative images from 3 independent experiments. (D) Fluorescence intensity quantifications (arbitrary units) of NCAM immunohistochemistry. (N=3 animals per group, 3≥ islets per animal: t-test *p<0.05). (E) Levels of transcripts for NCAM ( Ncam1 ), E-cadherin ( Cdh1 ), Connexin 36 ( Gjd2 ), and Pdx1 ( Pdx1 ) measured by qRT-PCR, normalized by 18S and shown relative to controls (Means ± SEM for islets from N= 5-6 animals per group: One sample t-test ****p< 0.0001, * p<0.05). ns or not significant: p>0.05.

    Journal: Frontiers in Endocrinology

    Article Title: Role of Delta/Notch-like EGF-related receptor in blood glucose homeostasis

    doi: 10.3389/fendo.2023.1161085

    Figure Lengend Snippet: β-cell-cell contacts are disturbed in β-Dner cKO islets due to decreased expression of cell adhesion markers. (A) Immunohistochemistry for E-cadherin (green) and Pdx1 (magenta). Scale bars: 25μm. Representative images from 3 independent experiments. (B) Fluorescence intensity quantifications (arbitrary units) of E-cadherin immunohistochemistry in islets identified by Pdx1-positive immunohistochemistry and exocrine cells identified by DAPI-based nuclear morphology. (N= 3-4 animals per group, 2≥ islets per animal: t-test *p<0.05, ns p>0.05). (C) Immunohistochemistry for NCAM (green) shown in islets and innervating axons on the pancreas. Scale bars: 25μm. Representative images from 3 independent experiments. (D) Fluorescence intensity quantifications (arbitrary units) of NCAM immunohistochemistry. (N=3 animals per group, 3≥ islets per animal: t-test *p<0.05). (E) Levels of transcripts for NCAM ( Ncam1 ), E-cadherin ( Cdh1 ), Connexin 36 ( Gjd2 ), and Pdx1 ( Pdx1 ) measured by qRT-PCR, normalized by 18S and shown relative to controls (Means ± SEM for islets from N= 5-6 animals per group: One sample t-test ****p< 0.0001, * p<0.05). ns or not significant: p>0.05.

    Article Snippet: Pdx1-CreER mouse , Tg(Pdx1-cre/Esr1*) #Dam/J; Pdx1- cre/Esr1*Dam , The Jackson Laboratory , MGI: 5008261.

    Techniques: Expressing, Immunohistochemistry, Fluorescence, Quantitative RT-PCR